May 2, 2016 — Starting at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 annual meeting May 4-6, SCAI will begin efforts to collect real data on the impact of radiation-induced cataracts amongst the cardiovascular cath lab team.

Through the IC-CATARACT initiative led by Manos Brilakis, M.D., Ph.D., FSCAI, and his team of researchers from VA North Texas Healthcare System and UT Southwestern Medical Center, will offer free eye exams at the SCAI meeting in the IC-CATARACT suite in the exhibit hall. 

Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease.

April 29, 2016 — AtriCure Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.

American Society of Nuclear Cardiology

New this year, the event offers attendees the chance to share questions, ideas and opinions during live sessions, creating a collaborative, educational and unforgettable experience. This new feature of our meeting app provides presenters and attendees with a powerful engagement tool, while keeping anonymity.

Using new high-resolution microscopy, researchers have found that molecular struts called microtubules (MT) interact with the heart’s contractile machinery to provide mechanical resistance for the beating of the heart.

Konica Minolta introduced the latest version of the Sonimage HS1 compact ultrasound system, enabling improved image quality, streamlined workflow and new cardiac functionality for the point-of-care ultrasound market.

Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for use in a magnetic resonance imaging (MRI) environment.

April 28, 2016 — Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences (ICES) and the Ted Rogers Centre for Heart Research, University Health Network (UHN). The study was published April 18 in the Journal of Clinical Oncology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now